Evogene to Showcase Advances at 24th Schrödinger European User Group Meeting in Munich
Evogene to Present at the 24th Schrödinger European User Group Meeting
Evogene Ltd., a leading entity in the field of computational chemistry, is all set to make a significant impact at the upcoming 24th Schrödinger European User Group Meeting scheduled from May 19 to 21, 2026, in Munich, Germany. This event, highly anticipated within the industry, aims to bring together key players from both academia and industry to discuss the latest advancements and practical applications in computational drug discovery.
A Platform for Innovation
Evogene has established itself as a trailblazer in using generative AI for the design of small molecules, an approach pivotal for both pharmaceutical and agricultural sectors. The company's innovative technology, ChemPass AITM, enables the exploration of vast chemical landscapes to identify novel compounds that meet stringent criteria of potency and effectiveness.
The meeting will feature Evogene's Dr. Roberto Olender, Head of Algorithms, who will present significant progress in the creation of generative designs for new compounds. His session, titled "Project Advancements Through Custom Computational Models", promises to showcase how tailored computational strategies can propel drug discovery efforts beyond traditional limitations.
Key Session Details
The schedule highlights a key session focused on small molecule drug design, where global experts will convene:
- - Date: May 20, 2026
- - Time: 11:00 AM - 12:30 PM CEST
- - Topics:
Presented by Christoph Grebner, Sanofi
- Multi-objective GenAI Foundation Model for De Novo Design of Molecules
Presented by Dr. Roberto Olender, Evogene
Collaboration and Networking Opportunities
Evogene views its participation at the Schrödinger Meeting as an invaluable opportunity to engage with existing and potential collaborators, researchers, and industry partners. Establishing connections in this environment could lead to synergies that foster innovation in drug discovery methodologies, paving the way for breakthroughs that address unmet medical needs.
Evogene’s Commitment to Innovation
As a company grounded in scientific excellence, Evogene is dedicated to bridging the gap between cutting-edge research and practical applications that respond to real-world challenges. Their continuous development of AI technologies places them in a unique position to facilitate rapid advancements in chemical discovery and design.
With strong strategic partnerships and a commitment to internal product development, Evogene is poised to shape the future of pharmaceutical and agricultural innovations significantly.
Conclusion
Evogene Ltd. remains a pivotal player in shaping the future of drug development through the amalgamation of technology and science. The upcoming Schrödinger European User Group Meeting symbolizes a platform where ideas converge and innovation flourishes, and Evogene is excited to be at the forefront of these discussions.
To learn more about Evogene and its initiatives, visit Evogene’s official website.
Disclaimer: This article contains forward-looking statements regarding future events. These statements involve risks and uncertainties that may result in actual outcomes differing from those projected. For more information on risk factors, refer to Evogene’s reports filed with applicable securities authorities.
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.